II.4.7 Hormonal Male Contraception
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Reliable and reversible hormonal contraceptive methods for men, comparable to modern female methods, have been identified, and selected regimens are under active development through the collaboration of andrologists, public sector agencies and pharmaceutical industries.
■ Clinical studies employing prototype drugs have demonstrated that the hormonal approach to switching off spermatogenesis provides contraceptive efficacy and is reversible with short-term safety. ■ No regimen yet achieves consistent azoospermia in all men, although testosterone administration to men in China and Indonesia gets close. ■ Combination regimens involving a second gonadotrophin-suppressing agent, usually a progestin, combined with testosterone achieve close to the ideal of universal suppression of spermatogenesis and contraceptive efficacy.
Summary
II.4.7.1 Introduction
Pituitary gonadotrophin [luteinizing hormone (LH), follicle-stimulating hormone (FSH)] secretion leading to high levels of intratesticular testosterone is essential for inducing spermatogenesis. Yet, because the hypothalamo-pituitary testicular axis is a tightly regulated negative feedback system, exogenous testosterone has the seemingly paradoxical effect of switching off spermatogenesis by suppressing pituitary gonadotrophin secretion and thereby depleting intratesticular testosterone (Handelsman 2005) . Androgen-induced reversible suppression of human spermatogenesis has long been known (Heckel 1939) . Extensive dose-finding and feasibility studies have established that injections of testosterone (T) esters, mostly involving weekly intramuscular injections of testosterone enanthate in an oily vehicle, induced azoospermia in most but not all men (Patanelli 1977; Schearer et al. 1978) . While these studies demonstrated that the hormonal approach was reversible and had reassuring shortterm safety, the degree of sperm suppression required to provide acceptable contraceptive efficacy remained uncertain (Patanelli 1977) . This issue was resolved by two large World Health Organization (WHO) clinical trials, the first male contraceptive efficacy studies, which established that azoospermia induced by weekly injections of testosterone enanthate provided highly reliable and reversible contraception (WHO 1990 (WHO , 1996 Waites 2003) . More recently, a second contraceptive efficacy study using a depot androgen/progestin combination found high levels of spermatogenic suppression with all men achieving azoospermia and no pregnancies occurring among 55 couples during 35.5 person years of exposure (Turner et al. 2003) .
II.4.7.2 Androgens Alone as Hormonal Contraceptives
Testosterone is potentially the ideal single contraceptive agent as it provides both gonadotrophin suppression and androgen replacement . The WHO clinical trials involving 671 men in 10 countries established that 98 % of all men had sperm suppression to < 3 million/ml by 3 -4 months (a similar rate to that after vasectomy) and that no pregnancies occurred when the men were azoospermic (WHO 1990 (WHO , 1996 . In the subgroup with residual sperm (0.1 -3 million/ml) in the ejaculate, there were only four pregnancies in 49.5 person years; the contraceptive failure rate in the non-azoospermic subgroup (~8 % per annum) was proportional to residual sperm concentration. Based on these results, the ideal goal is to achieve universal azoospermia, although the realistic minimal objective is to have <1 million residual sperm per millilitre to give an acceptable failure rate (Nieschlag 2002) .
These WHO trials also revealed that > 90 % Asian men suppressed to azoospermia compared to onlỹ 60 % of Caucasian men, an unexplained population variation in testosterone-induced azoospermia (Handelsman et al. 1995) . After cessation of testosterone, sperm reappeared within 3 months and returned to normal sperm output by 6 months. Discontinuations for acne, weight gain, polycythaemia or behavioural effects were few and readily reversible, as were changes in haemoglobin, testis size and plasma urea. There was no short-term evidence of liver, prostate or cardiovascular disorders (WHO 1990 (WHO , 1996 Wu et al. 1996) .
II.4.7.3 Pharmacokinetic Considerations
Weekly injections are clearly impractical and testosterone enanthate caused supraphysiological levels of testosterone which may have contributed to the incomplete spermatogenic suppression. Longer-acting depot preparations with more stable steady-state pharmacokinetics have therefore been developed: subdermal T pellets (Handelsman et al. 1990 ), T-loaded biodegradable microspheres (Amory et al. 2002) , and the newer injectable preparations, T undecanoate (Gu et al. 2002) and T buciclate (Behre et al. 1995) . All sustain physiological T levels for 2 -6 months. Monthly injections of T undecanoate have demonstrated high contraceptive efficacy in Chinese men (Gu et al. 2002) . Although synthetic androgens, including esters and a 7-methyl derivative of nandrolone, have been trialled by parenteral and oral routes, none yet offers greater efficacy or safety than testosterone itself (Kamischke and Nieschlag 2004; Handelsman 2005) .
II.4.7.4 Safety
The safety of exogenous androgen administration concerns potential effects on cardiovascular and prostatic disease and idiosyncratic effects such as polycythaemia and sleep apnoea. The available short-term studies have generally revealed no safety concerns but longterm surveillance of actual disease endpoints rather than surrogate markers would be required, as it was for female hormonal contraception. The relationship between androgens and prostatic disease and any influence of exogenous androgens remains poorly understood. Prospective studies show little direct relationship between endogenous T levels and prostatic disease (Shaneyfelt et al. 2000) . In situ prostate cancer is common in older men whereas rates of invasive prostate cancer vary considerably between populations despite similar blood T concentrations. Similarly, the relationship between androgens and cardiovascular disease are complex and poorly understood Wu and von Eckardstein 2003) so that the risks, if any, from exogenous androgens in normal men cannot be predicted with any certainty. Idiosyncratic androgen effects such as polycythaemia and sleep apnoea are rare (< 1 %) and age-dependent so that the use of physiological doses of, and delivery systems for, T in a relatively young population minimize these risks. Clearly, for contraceptive purposes, it is prudent not to exceed physiological levels of androgen and to monitor longterm for cardiovascular and prostatic disease risk Handelsman 2005) .
II.4.7.5 Combination Regimens as Hormonal Contraceptives
Second, non-androgenic, agents that suppress gonadotrophins include progestins, oestrogens and gonadotrophin-releasing hormone (GnRH) antagonists. Progestins are more affordable and numerous synthetic progestins are used in female contraception with oestrogen replacement therapy. They are potent inhibitors of gonadotrophin secretion and of endogenous T, and suppress spermatogenesis but require androgen supplementation to avoid androgen deficiency (Heller et al. 1959; Frick et al. 1981) . In practice, androgen-progestin combinations achieve equally high rates of azoospermia as with androgens alone, approaching uniform suppression in all populations. This reduces the
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practical importance of the population differences for contraception found with androgens alone, although it has implications for understanding population differences in hormone-dependent diseases.
II.4.7.6 Efficacy of Combination Regimens
Such combinations have shown important improvements in the efficacy of spermatogenic suppression (Bebb et al. 1996; Handelsman et al. 1996; Meriggiola et al. 1996) possibly by reducing the impact of residual T in supporting persistent spermatogenesis (Bouchard and Garcia 1987; Behre et al. 1992 ). Many studies with medroxyprogesterone acetate (MPA) given orally or by injection, combined with T by injection or by dermal gels, produce azoospermia (Patanelli 1977; Schearer et al. 1978 ). The azoospermia is nearly uniform in Indonesian men (Pangkahila 1991; WHO 1993) , as it is in Caucasian men when the T is given as a depot implant (Handelsman et al. 1996) . Oral progestins, e.g. levonorgestrel (Foegh 1983; Bebb et al. 1996; Anawalt et al. 1999 ) and norethisterone (Guerin and Rollet 1988; Lobel et al. 1989 ) and cyproterone acetate (Meriggiola et al. 1996 (Meriggiola et al. , 1998 have high efficacy when combined with T. Highly effective suppression of spermatogenesis also occurs with depot progestins, e.g. norgestrel (Gonzalo et al. 2002 ), etonogestrel (Anderson et al. 2002 , depot injectable MPA (Handelsman et al. 1996; Turner et al. 2003) or norethisterone (Kamischke et al. 2002) when combined with T. A contraceptive efficacy study using a depot androgen/ progestin combination found high levels of spermatogenic suppression, with all men achieving azoospermia and no pregnancies occurring among 55 couples during 35.5 person years of exposure (Turner et al. 2003) .
Spermatogenesis recovers to normal post treatment but at a slower rate than with androgen alone, possibly due to prolonged residual depot effects (Handelsman 2005) .
II.4.7.7 Gonadotrophin Blockade: GnRH Analogues
GnRH agonists or GnRH antagonists when combined with T replacement suppress gonadotrophins and spermatogenesis. GnRH superactive agonists achieve this by gradual desensitization of the GnRH receptors, a paradoxical response that takes days to weeks until the initial stimulation of gonadotrophin and T secretion abate, after which prolonged use achieves functional antagonism with lowered gonadotrophin and testosterone secretion. However, GnRH agonists remain partial agonists and these more affordable analogues rarely achieve azoospermia (Bouchard and Garcia 1987; Lunn et al. 1990; Behre et al. 1992) . Pure GnRH antagonists, on the other hand, sustain immediate competitive blockade of GnRH receptors (Marshall et al. 1986 ) and in combination with T produce rapid, sustained and reversible spermatogenesis in men (Pavlou et al. 1991; Tom et al. 1992) . Although modern GnRH antagonists retain some local irritation at the injection site, they otherwise have few side-effects and prolonged depot release formulations are under development, as are non-peptide GnRH antagonists.
II.4.7.8 Immunoneutralization as a Contraceptive Approach
Immunoneutralization of GnRH is not likely to be a safe and effective option for contraception (Handelsman 2005) . However, immunological blockade of FSH action by vaccination theoretically offered the attractive possibility of inhibiting spermatogenesis by disrupting Sertoli cell function but without inhibiting endogenous T production. Although FSH was considered essential for human spermatogenesis, spermatogenesis and fertility persist in rodents (Singh et al. 1995; Kumar et al. 1997; Dierich et al. 1998 ) and humans (Tapanainen et al. 1997 ) lacking FSH bioactivity. Hence even complete FSH blockade might produce insufficient reduction in sperm output and function required for adequate contraceptive efficacy (Nieschlag 1986 ). In addition to the usual safety concerns of contraceptive vaccines, including autoimmune hypophysitis, orchitis or immune-complex disease, an FSH vaccine might be overcome by reflex increases in pituitary FSH secretion. 
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Summary
Transsexualism is the condition in which a person with apparently normal somatic sexual differentiation of one gender is convinced that he or she is actually a member of the opposite gender. It is associated with an irresistible urge to be that gender hormonally, anatomically and psychosocially. In 2004, the international organization involved with professional help to transsexuals, the Harry Benjamin International Gender Dysphoria Association, drafted Standards of Care (SOC) available at http:// www.hbigda.org. The major purpose of the SOC is to articulate this organization's professional consensus about the psychological, medical and surgical management of gender identity disorders. These standards provide guidance to professionals practising in this area, who often work in isolation from mainstream medicine. It may also be of help in legal medicine to identify professional standards. Persons with gender identity disorders, their families and social institutions may use the SOC as a means to understand the current thinking of professionals.
Before initiating hormonal or surgical treatment that will change a person's gender, the physician should counsel the patient about realistic expectations from treatment. The only benefit sex reassignment can bring is relief of gender dysphoria; all human problems outside the area of gender dysphoria will remain. Unrealistic expectations that subjects may have of the success of hormonal and surgical treatment for their transition to the desired sex must be addressed. Contacts with other transsexuals who are already in the process of changing over to the new sex or who have completed this process may be helpful in shaping a subject's expectations of what can be achieved and what problems, personally and socially, may arise in the transition to the new sex.
II.4.8.1 Real Life Test
When hormone treatment starts, or maybe even earlier, the "real life test" should begin. It is an extended period of full-time living as a member of the desired sex. The "real life test" allows the subject and the attending professional to monitor the experience in the new sex status as he/she habituates his/her responses to other people. Without this test of how others react and how he/ she reacts to others, the subject knows only his/her private convictions and fantasies of being a member of the opposite sex. Convictions and fantasies may be unrealistic and may lead to magical expectations of life in the new sex.
Embarking on the "real life test" may be done in a stepwise fashion; for instance, first in a trusted environment and later in public. The subject should have lived at least one full year full-time in the new sex before irreversible surgical reassignment is considered.
